August 4, 2020
Ono Pharmaceutical said on August 3 that the anti-PD-1 antibody Opdivo (nivolumab) in combination with the anti-VEGF antibody bevacizumab and chemotherapy hit the primary endpoint in a PIII study with non-squamous non-small cell lung cancer (NSCLC) by extending progression-free survival...read more